Skip to main navigation Skip to search Skip to main content

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

  • Jennifer A Chan
  • , Susan Geyer
  • , Tyler Zemla
  • , Michael V Knopp
  • , Spencer Behr
  • , Sydney Pulsipher
  • , Fang-Shu Ou
  • , Amylou C Dueck
  • , Jared Acoba
  • , Ardaman Shergill
  • , Edward M Wolin
  • , Thorvardur R Halfdanarson
  • , Bhavana Konda
  • , Nikolaos A Trikalinos
  • , Bernard Tawfik
  • , Nitya Raj
  • , Shagufta Shaheen
  • , Namrata Vijayvergia
  • , Arvind Dasari
  • , Jonathan R Strosberg
  • Elise C Kohn, Matthew H Kulke, Eileen M O'Reilly, Jeffrey A Meyerhardt
  • Dana-Farber Cancer Institute
  • Alliance Statistics and Data Management Center
  • University of Cincinnati
  • University of California at San Francisco
  • University of Hawaii Cancer Center
  • Alliance Protocol Operations Office, University of Chicago, Chicago
  • Mount Sinai Medical Center, New York, NY
  • Mayo Clinic Comprehensive Cancer, Rochester MN
  • Ohio State University Comprehensive Cancer Center
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • University of New Mexico Comprehensive Cancer Center, Albuquerque NM
  • Memorial Sloan-Kettering Cancer Center
  • University of Chicago
  • University of Texas MD Anderson Cancer Center
  • Moffitt Cancer Center
  • National Cancer Institute
  • Boston University

Research output: Contribution to journalArticlepeer-review

152 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science